In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer
In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer
Abstract Many agents are being studied for the treatment of metastatic breast cancer (MBC), yet few studies have demonstrated longer overall survival (OS), the primary measure of clinical benefit in MBC. This paper examines the key endpoints in clinical trials and U.S. Food and Drug Administration (FDA) approvals of drugs …